我要投票 同济堂在中草药行业中的票数:586
· 外 推 电 报 ·
2025-08-06 21:50:17 星期三

【同济堂是哪个国家的品牌?】

同济堂是什么牌子?「同济堂」是国药集团同济堂(贵州)制药有限公司旗下著名品牌。该品牌发源于贵州,由创始人朱鹤在2005-06-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力同济堂品牌出海!将品牌入驻外推网,定制同济堂品牌推广信息,可以显著提高同济堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

贵州同济堂制药有限公司是一家历史悠久的企业,是贵州中药行业闻名遐迩的老字号。同济堂始创于清光绪十四年(公元1888年),至今已有120多年的悠久历史。100多年来,同济堂把“同心协力,济世活人”作为永恒的精神,始终坚持传统中药特色,弘扬中华医药文化。以质量为优、便民服务之举而闻名省内外。是贵州省唯一获得国家授予“中华老字号”殊荣的医药企业。2008年,同济堂中药文化入选“第二批国家级非物质文化遗产”名录,成为国家重点保护的非物质文化遗产。

近年来,贵州同济堂已发展成为一家集科研、生产、销售、种植为一体,拥有贵州同济堂药品配送有限公司、贵州同济堂中药饮片有限公司、贵州同济堂药房连锁有限公司、贵州老来福药业、安徽精方药业、青海普兰特制药公司等十余家子公司的高科技集团化企业。在职员工3000多人。贵州同济堂制药有限公司现分别在贵阳市修文县和贵阳市小河区建立药品生产基地,通过GMP认证的生产线十一条,可生产胶囊剂、片剂、颗粒剂、锭剂、糖浆剂、酊剂、口服溶液剂、膏剂等十二种剂型。

目前,贵州同济堂制药有限公司有中西药品种达140多种,拥有自主知识产权的专利产品七个。其中11种现代化中药和59种西药列入《国家基本医疗保险和工伤保险药品目录》。

“仙灵骨葆胶囊”、“颈舒颗粒”、“润燥止痒胶囊”、“枣仁安神胶囊”和“风湿骨痛胶囊(片)”分别作为独家品种进入《2012版国家基本药物目录》。各产品凭借其确切而显著的疗效,在全国医药市场享有较高声誉,“同济堂”、“仙灵”、“仙灵骨葆”品牌已成为中国驰名商标。

2009年,美国信纳克医学研究中心关于“仙灵骨葆胶囊治疗绝经后骨质疏松症临床疗效研究”成果,在全球最权威的新英格兰杂志发表。这是首个关于中成药的循证医学国际权威机构认证结果。它标志着世界骨科治疗领域首次加入了中成药元素。中成药治疗骨病的历史从此掀开新的篇章。

在新产品研发方面,我们投入大量资金新建符合GLP要求的中心实验室用于新药的研制和现有药品的二次开发,研究人员为长期从事药物研究的专家、教授和专业技术人才,所开发药品技术含量高,疗效确切,为公司长远发展奠定了坚实的基础。

自1998年来,公司连续获得“贵阳市文明单位”、“贵阳市农业产业化重点龙头企业”、“贵州省纳税先进单位”、“贵州省区(县)先进企业”、“贵州省农业银行特级三A信用单位”、“贵阳市重合同守信用企业”、“贵阳市非公有制优势企业”等称号。“仙灵骨葆胶囊”填补了中成药治疗骨质疏松的空白,先后荣获“世界骨伤科联合会”科技进步一等奖、“中国骨伤科协会”特别贡献奖、贵州省优秀产品一等奖、“贵阳市科技创新一等奖”、“贵阳市科技创新特等奖”等诸多荣誉。

英文翻译:Guizhou Tongjitang Pharmaceutical Co., Ltd. is an enterprise with a long history, which is a famous time-honored brand in Guizhou traditional Chinese medicine industry. Tongjitang was founded in the 14th year of Guangxu in the Qing Dynasty (1888 AD), and has a long history of more than 120 years. For more than 100 years, Tongjitang has always adhered to the characteristics of traditional Chinese medicine and carried forward the Chinese medicine culture with the eternal spirit of "working together to save the world and the living". It is famous for its excellent quality and convenient service. It is the only pharmaceutical enterprise in Guizhou Province that has won the national award of "China time honored brand". In 2008, Tongjitang traditional Chinese medicine culture was selected into the list of "the second batch of national intangible cultural heritage", becoming a national key protected intangible cultural heritage. In recent years, Guizhou Tongjitang has developed into a high-tech group enterprise integrating scientific research, production, sales and planting, with more than ten subsidiaries including Guizhou Tongjitang Pharmaceutical Distribution Co., Ltd., Guizhou Tongjitang Herbal Pieces Co., Ltd., Guizhou Tongjitang pharmacy chain Co., Ltd., Guizhou Laolaifu Pharmaceutical Co., Ltd., Anhui Jingfang Pharmaceutical Co., Ltd., Qinghai plante Pharmaceutical Co., Ltd 。 More than 3000 employees. Guizhou Tongjitang Pharmaceutical Co., Ltd. has established drug production bases in Xiuwen County and Xiaohe District of Guiyang City, respectively. There are 11 GMP certified production lines, which can produce 12 dosage forms, including capsules, tablets, granules, pastilles, syrups, tinctures, oral solutions and plasters. At present, Guizhou Tongjitang Pharmaceutical Co., Ltd. has more than 140 kinds of Chinese and Western medicines and seven patented products with independent intellectual property rights. Among them, 11 kinds of modern Chinese medicine and 59 kinds of Western medicine are listed in the catalogue of national basic medical insurance and industrial injury insurance drugs. "Xianlinggubao capsule", "Jingshu Granule", "Runzaozhiyang capsule", "Zaoren Anshen capsule" and "Fengshigutong capsule (tablet)" were respectively included in the 2012 edition of national basic drug catalogue as exclusive varieties. Each product enjoys a high reputation in the national pharmaceutical market with its exact and significant curative effect, "Tongjitang", "Xianling", "Xianlinggubao" brand has become a well-known trademark in China. In 2009, the research results of "clinical efficacy of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis" published in the most authoritative New England Journal. This is the first evidence-based medicine certification result about Chinese patent medicine. It marks the first time that traditional Chinese medicine has been added to the world orthopedic treatment field. The history of Chinese patent medicine treating osteopathy has opened a new chapter. In the aspect of new product research and development, we have invested a lot of money to build a new central laboratory that meets the requirements of GLP for the research and development of new drugs and the secondary development of existing drugs. The researchers have laid a solid foundation for the long-term development of the company for the experts, professors and professional technical personnel who have been engaged in drug research for a long time with high technical content and precise curative effect. Since 1998, the company has been awarded the titles of "Guiyang civilized unit", "key leading enterprise of agricultural industrialization in Guiyang", "advanced unit of tax payment in Guizhou Province", "advanced enterprise in Guizhou Province (county)", "special class 3A credit unit of Agricultural Bank of Guizhou Province", "contract abiding and credit abiding enterprise in Guiyang city", "non-public dominant enterprise in Guiyang city" and so on. "Xianlinggubao capsule" has filled in the blank of Chinese patent medicine in the treatment of osteoporosis. It has successively won the first prize of science and technology progress of "world Orthopedic Association", "special contribution award of China Orthopedic Association", "first prize of excellent products of Guizhou Province", "first prize of Science and technology innovation of Guiyang city", "special prize of science and technology innovation of Guiyang city" and many other honors.

本文链接: https://www.waitui.com/brand/678835060.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

*ST亚振:股票交易异常波动,停牌核查

36氪获悉,*ST亚振公告,公司股票于2025年8月4日、5日、6日连续三个交易日内日收盘价格涨幅偏离值累计达到12%,属于股票交易异常波动。公司股票短期涨幅与同期上证指数、家具制造业存在严重偏离。公司将就股票交易情况进行核查,经申请,公司股票自2025年8月7日开市起停牌,自披露核查公告后复牌,预计停牌时间不超过10个交易日。公司提醒广大投资者注意二级市场交易风险。

2小时前

Shopify第二季度营收26.8亿美元,超出市场预期

Shopify美股盘前涨超10%。公司第二季度营收26.8亿美元,市场预估25.5亿美元;二季度订阅收入6.56亿美元,市场预估6.591亿美元;二季度营业利润2.91亿美元,市场预估2.477亿美元。(界面)

2小时前

理想汽车、中国汽研、东风柳汽发布联合声明

36氪获悉,理想汽车、中国汽研、东风柳汽发布联合声明:三方共同倡议:严守自律底线,共塑良性竞合:呼吁汽车行业严格自律,在产品研发、测试验证及宣传推广中,恪守诚信原则与商业道德,杜绝诸如贬损性对比等任何形式的不当竞争行为。检测认证机构应坚守专业准则,确保测试流程科学严谨,信息发布真实、准确、完整,共同维护风清气正的市场秩序。

2小时前

塔牌集团:拟5000万元—1亿元回购公司股份

36氪获悉,塔牌集团公告,拟5000万元—1亿元回购公司股份,用于公司实施员工持股计划,回购价格不超过10元/股(含)。

2小时前

三部门:到2027年全国完成新改建农村公路30万公里

36氪获悉,交通运输部、财政部、自然资源部印发《新一轮农村公路提升行动方案》,到2027年,全国完成新改建农村公路30万公里,便捷高效、普惠公平的农村公路网络基本建成;实施修复性养护工程30万公里,技术状况优良路率保持在70%以上,实施安全生命防护工程15万公里,改造危旧桥梁(含生命通道渡改桥、漫水桥)9000座,农村公路安全和服务保障能力进一步提升。

2小时前

本页详细列出关于同济堂的品牌信息,含品牌所属公司介绍,同济堂所处行业的品牌地位及优势。
咨询